Estrogen replacement therapy and breast cancer
Zahl, P-Henrik.; Maehlen, J.
Tidsskrift for den Norske Laegeforening Tidsskrift for Praktisk Medicin Ny Raekke 125(8): 1045; Author Reply 1045
2005
ISSN/ISBN: 0029-2001 PMID: 15852091 Document Number: 584986
Document emailed within 1 workday
Related Documents
Brewster, W.R.; DiSaia, P.J.; Grosen, E.A.; McGonigle, K.F.; Kuykendall, J.L.; Creasman, W.T. 1999: An experience with estrogen replacement therapy in breast cancer survivors International Journal of Fertility and Women's Medicine 44(4): 186-192Spicer, D.; Pike, M.C.; Henderson, B.E. 1990: The question of estrogen replacement therapy in patients with a prior diagnosis of breast cancer Oncology 4(12): 49-54 59; Discussion 59 62
Santen, R.J.; Pinkerton, J.; McCartney, C.; Petroni, G.R. 2001: Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy Journal of Clinical Endocrinology and Metabolism 86(1): 16-23
2002: New SBU-report on estrogen replacement therapy in climacteric. Moderate risk of breast cancer after long-term use Lakartidningen 99(28-29): 3031-3034
Nachtigall, M.J.; Smilen, S.W.; Nachtigall, R.D.; Nachtigall, R.H.; Nachtigall, L.E. 1992: Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy Obstetrics and Gynecology 80(5): 827-830
Dargent, D. 2000: Estrogen replacement therapy in patients in remission after treatment for estrogen dependent cancer. Certainties are still lacking Gynecologie Obstetrique and Fertilite 28(6): 427-428
Trapido, E.J.; Brinton, L.A.; Schairer, C.; Hoover, R. 1984: Estrogen replacement therapy and benign breast disease Journal of the National Cancer Institute 73(5): 1101-1105
Glaser, A.N. 2000: Estrogen-progestin replacement and risk of breast cancer JAMA 284(6): 692; Author Reply 693-4
Tominaga, T.; Abe, O.; Izuo, M.; Isono, K.; Enomoto, K.; Nishi, M.; Fukami, A.; Muto, T.; Morioka, Y.; Watanabe, H. 1993: Correlations between estrogen receptor and prognostic factors of patients with breast cancer. the Kanto Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(14): 2171-2176
Rosenberg, L.; Palmer, J.R.; Shapiro, S. 1992: Oestrogen replacement therapy and breast cancer Results from the Slone Epidemiology Units Toronto Breast Cancer Study Mann, R D Hormone replacement therapy and breast cancer risk : 253-264
Persson, I. 1996: Cancer risk in women receiving estrogen-progestin replacement therapy Maturitas 23(Suppl): S37-S45
Calle, E.E.; Miracle-McMahill, H.L.; Thun, M.J.; Heath, C.W. 1995: Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women Journal of the National Cancer Institute 87(7): 517-523
Slater, C.C.; Zhang, C.; Hodis, H.N.; Mack, W.J.; Boostanfar, R.; Shoupe, D.; Paulson, R.J.; Stanczyk, F.Z. 2001: Comparison of estrogen and androgen levels after oral estrogen replacement therapy Journal of Reproductive Medicine 46(12): 1052-1056
Dryzhak, V.I. 1989: Estrogen antagonists and inhibitors in hormone therapy of breast cancer Voprosy Onkologii 35(7): 771-778
This, P. 2005: Hormonal replacement therapy and breast cancer La Revue du Praticien 55(4): 377-382
Joseph, K.S. 1995: Breast cancer and hormone-replacement therapy New England Journal of Medicine 333(20): 1356; Author Reply 1357-1358
Li, L.; Ji, J.; Wang, J.-B.; Niyazi, M.; Qiao, Y.-L.; Boffetta, P. 2012: Attributable causes of breast cancer and ovarian cancer in china: reproductive factors, oral contraceptives and hormone replacement therapy Chinese Journal of Cancer Research 24(1): 9-17
Magnusson, C.; Weiderpass, E. 2001: Hormone therapy in climacteric. Different effects of estrogen and gestagen on the risk of breast and endometrial cancer Lakartidningen 98(5): 418-421
Rubens, R.D.; Hayward, J.L. 1980: Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer Cancer 46(12 Suppl): 2922-2924
Nomura, Y.; Abe, Y.; Yamagata, J.; Takenaka, K. 1976: Possible retention of the estrogen-binding capacity after endocrine ablation therapy in the rat and human breast cancer Gan 67(1): 101-104